> top > docs > PubMed:32522282 > annotations

PubMed:32522282 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 27-39 DG_6 denotes Azithromycin
T2 44-62 DG_20 denotes HydroxyChloroquine
T3 44-62 CHEBI:5801 denotes HydroxyChloroquine
T4 44-62 CHEBI:5801 denotes HydroxyChloroquine
T5 93-101 SP_7 denotes COVID-19
T6 305-315 CHEBI:33282 denotes antibiotic
T7 305-315 CHEBI:33282 denotes antibiotic
T8 316-328 CHEBI:2955 denotes azithromycin
T9 316-328 CHEBI:2955 denotes azithromycin
T10 316-328 DG_6 denotes azithromycin
T11 333-351 CHEBI:5801 denotes hydroxychloroquine
T12 333-351 CHEBI:5801 denotes hydroxychloroquine
T13 333-351 DG_20 denotes hydroxychloroquine
T14 374-380 UBERON:0002405 denotes immune
T15 381-391 GO:0065007 denotes modulation
T16 513-521 SP_7 denotes COVID-19
T17 656-675 UBERON:0007221 denotes intensive care unit
T18 680-685 GO:0016265 denotes death
T19 1090-1101 UBERON:0001004 denotes respiratory
T20 1208-1216 SP_7 denotes COVID-19
T21 1329-1337 GO:0007565 denotes pregnant
T22 1353-1362 GO:0007565 denotes pregnancy
T23 1458-1466 GO:0042696 denotes menarche
T24 1496-1508 GO:0042703 denotes menstruation
T25 1621-1625 CHEBI:17544 denotes FiO2
T26 1621-1625 CHEBI:17544 denotes FiO2
T27 1670-1682 CHEBI:28619 denotes azithromycin
T28 1670-1682 CHEBI:28619 denotes azithromycin
T29 1670-1682 DG_6 denotes azithromycin
T30 1686-1704 CHEBI:5801 denotes hydroxychloroquine
T31 1686-1704 CHEBI:5801 denotes hydroxychloroquine
T32 1686-1704 DG_20 denotes hydroxychloroquine
T33 1728-1735 CHEBI:15854 denotes quinine
T34 1728-1735 CHEBI:15854 denotes quinine
T35 1739-1740 CHEBI:51231 denotes 4
T36 1739-1740 CHEBI:51231 denotes 4
T37 1740-1741 CHEBI:86228 denotes -
T38 1740-1741 CHEBI:86228 denotes -
T39 1741-1755 CHEBI:36709 denotes aminoquinoline
T40 1741-1755 CHEBI:36709 denotes aminoquinoline
T41 1781-1788 GO:0007605 denotes hearing
T42 1836-1842 GO:0007601 denotes Visual
T43 1882-1887 UBERON:0002107 denotes liver
T44 1953-1969 UBERON:0001555 denotes gastrointestinal
T45 1971-1983 UBERON:0001016 denotes neurological
T46 2087-2094 UBERON:0000948 denotes cardiac
T47 2217-2224 CHEBI:4551 denotes digoxin
T48 2217-2224 CHEBI:4551 denotes digoxin
T49 2228-2235 CHEBI:17234 denotes Glucose
T50 2228-2235 CHEBI:17234 denotes Glucose
T51 2235-2238 CHEBI:14314 denotes -6-
T52 2235-2238 CHEBI:14314 denotes -6-
T53 2238-2247 CHEBI:18367 denotes phosphate
T54 2238-2247 CHEBI:18367 denotes phosphate
T55 2302-2307 UBERON:0000178 denotes Blood
T56 2308-2315 CHEBI:17234 denotes glucose
T57 2308-2315 CHEBI:17234 denotes glucose
T58 2514-2519 CHEBI:16933 denotes ergot
T59 2514-2519 CHEBI:16933 denotes ergot
T60 2520-2529 CHEBI:23943 denotes alkaloids
T61 2520-2529 CHEBI:23943 denotes alkaloids
T62 2568-2575 CHEBI:4551 denotes digoxin
T63 2568-2575 CHEBI:4551 denotes digoxin
T64 2618-2624 UBERON:0002081 denotes atrial
T65 2671-2685 UBERON:0004535 denotes Cardiovascular
T66 2825-2832 CHEBI:4551 denotes digoxin
T67 2825-2832 CHEBI:4551 denotes digoxin
T68 2914-2918 CHEBI:23888 denotes drug
T69 2914-2918 CHEBI:23888 denotes drug
T70 3473-3485 CHEBI:2955 denotes Azithromycin
T71 3473-3485 DG_6 denotes Azithromycin
T72 3473-3485 CHEBI:2955 denotes Azithromycin
T73 3658-3665 UBERON:0000945 denotes stomach
T74 3666-3673 GO:0007631 denotes feeding
T75 3722-3736 CHEBI:3732 denotes clarithromycin
T76 3722-3736 DG_11 denotes clarithromycin
T77 3722-3736 CHEBI:3732 denotes clarithromycin
T78 3963-3975 CHEBI:2955 denotes azithromycin
T79 3963-3975 DG_6 denotes azithromycin
T80 3963-3975 CHEBI:2955 denotes azithromycin
T81 3991-4009 CHEBI:5801 denotes Hydroxychloroquine
T82 3991-4009 DG_20 denotes Hydroxychloroquine
T83 3991-4009 CHEBI:5801 denotes Hydroxychloroquine
T84 4057-4075 CHEBI:5801 denotes hydroxychloroquine
T85 4057-4075 DG_20 denotes hydroxychloroquine
T86 4057-4075 CHEBI:5801 denotes hydroxychloroquine
T87 4350-4359 UBERON:0002048 denotes Pulmonary
T88 4687-4691 UBERON:0002048 denotes lung
T89 4732-4744 UBERON:0005169 denotes interstitial
T90 4745-4749 UBERON:0002048 denotes lung

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 759-762 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T2 1882-1887 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T3 2228-2235 Body_part denotes Glucose http://purl.org/sig/ont/fma/fma82743
T4 2302-2307 Body_part denotes Blood http://purl.org/sig/ont/fma/fma9670
T5 2308-2315 Body_part denotes glucose http://purl.org/sig/ont/fma/fma82743
T6 2375-2381 Body_part denotes mental http://purl.org/sig/ont/fma/fma264279
T7 3658-3665 Body_part denotes stomach http://purl.org/sig/ont/fma/fma7148
T8 3955-3959 Body_part denotes back http://purl.org/sig/ont/fma/fma25056
T9 4687-4691 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T10 4745-4749 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 759-762 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T2 1882-1887 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T3 2302-2307 Body_part denotes Blood http://purl.obolibrary.org/obo/UBERON_0000178
T4 3658-3665 Body_part denotes stomach http://purl.obolibrary.org/obo/UBERON_0000945
T5 3674-3678 Body_part denotes tube http://purl.obolibrary.org/obo/UBERON_0000025
T6 4687-4691 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T7 4745-4749 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 93-101 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 361-373 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T3 447-457 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550
T4 513-521 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 1208-1216 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T6 1659-1666 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T7 1708-1724 Disease denotes hypersensitivity http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271
T9 1781-1793 Disease denotes hearing loss http://purl.obolibrary.org/obo/MONDO_0005365
T10 1796-1805 Disease denotes Psoriasis http://purl.obolibrary.org/obo/MONDO_0005083
T11 1808-1819 Disease denotes Retinopathy http://purl.obolibrary.org/obo/MONDO_0005283
T12 1882-1896 Disease denotes liver diseases http://purl.obolibrary.org/obo/MONDO_0005154
T13 1908-1918 Disease denotes amoebiasis http://purl.obolibrary.org/obo/MONDO_0005644
T14 1988-2011 Disease denotes hematological disorders http://purl.obolibrary.org/obo/MONDO_0005570
T15 2095-2115 Disease denotes conduction disorders http://purl.obolibrary.org/obo/MONDO_0007264
T16 2116-2127 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T17 2182-2199 Disease denotes Myasthenia gravis http://purl.obolibrary.org/obo/MONDO_0009688
T18 2228-2272 Disease denotes Glucose-6-phosphate dehydrogenase deficiency http://purl.obolibrary.org/obo/MONDO_0005775
T19 2275-2284 Disease denotes Porphyria http://purl.obolibrary.org/obo/MONDO_0019142|http://purl.obolibrary.org/obo/MONDO_0037939
T21 2287-2300 Disease denotes Hypoglycaemia http://purl.obolibrary.org/obo/MONDO_0004946
T22 2375-2389 Disease denotes mental illness http://purl.obolibrary.org/obo/MONDO_0002025
T23 2618-2637 Disease denotes atrial fibrillation http://purl.obolibrary.org/obo/MONDO_0004981
T24 4330-4367 Disease denotes Chronic Obstructive Pulmonary Disease http://purl.obolibrary.org/obo/MONDO_0005002
T25 4687-4700 Disease denotes lung diseases http://purl.obolibrary.org/obo/MONDO_0005275
T26 4702-4706 Disease denotes COPD http://purl.obolibrary.org/obo/MONDO_0005002
T27 4708-4714 Disease denotes asthma http://purl.obolibrary.org/obo/MONDO_0004979
T28 4716-4730 Disease denotes bronchiectasis http://purl.obolibrary.org/obo/MONDO_0004822
T29 4732-4757 Disease denotes interstitial lung disease http://purl.obolibrary.org/obo/MONDO_0015925
T30 4745-4757 Disease denotes lung disease http://purl.obolibrary.org/obo/MONDO_0005275

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 118-119 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T2 142-143 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 163-164 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 194-204 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T5 210-213 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T6 709-710 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T7 759-762 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T8 769-772 http://purl.obolibrary.org/obo/CLO_0053733 denotes 1:1
T9 1163-1165 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T10 1188-1190 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T11 1217-1221 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T12 1363-1367 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T13 1843-1848 http://purl.obolibrary.org/obo/UBERON_0007688 denotes field
T14 1882-1887 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T15 1882-1887 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T16 2044-2046 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T17 2175-2177 http://purl.obolibrary.org/obo/CLO_0007874 denotes ms
T18 2302-2307 http://purl.obolibrary.org/obo/UBERON_0000178 denotes Blood
T19 2302-2307 http://www.ebi.ac.uk/efo/EFO_0000296 denotes Blood
T20 2909-2913 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T21 3674-3678 http://purl.obolibrary.org/obo/UBERON_0000025 denotes tube
T22 4403-4404 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T23 4654-4657 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T24 4687-4691 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T25 4687-4691 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T26 4745-4749 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T27 4745-4749 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T28 4999-5002 http://purl.obolibrary.org/obo/CLO_0053733 denotes 1:1
T29 5506-5509 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T30 5549-5550 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T31 5620-5623 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 305-315 Chemical denotes antibiotic http://purl.obolibrary.org/obo/CHEBI_33281
T2 316-328 Chemical denotes azithromycin http://purl.obolibrary.org/obo/CHEBI_2955
T3 333-351 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T4 393-402 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T5 783-788 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T6 1102-1110 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T7 1135-1143 Chemical denotes medicine http://purl.obolibrary.org/obo/CHEBI_23888
T8 1670-1682 Chemical denotes azithromycin http://purl.obolibrary.org/obo/CHEBI_2955
T9 1686-1704 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T10 1728-1735 Chemical denotes quinine http://purl.obolibrary.org/obo/CHEBI_137041|http://purl.obolibrary.org/obo/CHEBI_15854
T12 1741-1755 Chemical denotes aminoquinoline http://purl.obolibrary.org/obo/CHEBI_36709
T13 2217-2224 Chemical denotes digoxin http://purl.obolibrary.org/obo/CHEBI_145795|http://purl.obolibrary.org/obo/CHEBI_4551
T15 2228-2235 Chemical denotes Glucose http://purl.obolibrary.org/obo/CHEBI_17234|http://purl.obolibrary.org/obo/CHEBI_4167|http://purl.obolibrary.org/obo/CHEBI_42758
T18 2238-2247 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T22 2308-2315 Chemical denotes glucose http://purl.obolibrary.org/obo/CHEBI_17234|http://purl.obolibrary.org/obo/CHEBI_4167
T24 2514-2529 Chemical denotes ergot alkaloids http://purl.obolibrary.org/obo/CHEBI_23943
T25 2520-2529 Chemical denotes alkaloids http://purl.obolibrary.org/obo/CHEBI_22315
T26 2568-2575 Chemical denotes digoxin http://purl.obolibrary.org/obo/CHEBI_145795|http://purl.obolibrary.org/obo/CHEBI_4551
T28 2718-2725 Chemical denotes Calcium http://purl.obolibrary.org/obo/CHEBI_22984
T29 2726-2736 Chemical denotes antagonist http://purl.obolibrary.org/obo/CHEBI_48706
T30 2786-2796 Chemical denotes amiodarone http://purl.obolibrary.org/obo/CHEBI_2663
T31 2825-2832 Chemical denotes digoxin http://purl.obolibrary.org/obo/CHEBI_145795|http://purl.obolibrary.org/obo/CHEBI_4551
T33 2914-2918 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T34 2941-2944 Chemical denotes ECG http://purl.obolibrary.org/obo/CHEBI_70255
T35 3005-3010 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T36 3024-3029 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T37 3276-3281 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T38 3296-3301 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T39 3336-3341 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T40 3427-3432 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T41 3722-3736 Chemical denotes clarithromycin http://purl.obolibrary.org/obo/CHEBI_3732
T42 3911-3916 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T43 3963-3975 Chemical denotes azithromycin http://purl.obolibrary.org/obo/CHEBI_2955
T44 4057-4075 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T45 4876-4881 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T46 5020-5025 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T47 5532-5538 Chemical denotes Letter http://purl.obolibrary.org/obo/CHEBI_6446

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 1659-1666 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T2 1708-1724 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T3 1781-1793 Phenotype denotes hearing loss http://purl.obolibrary.org/obo/HP_0000365
T4 1796-1805 Phenotype denotes Psoriasis http://purl.obolibrary.org/obo/HP_0003765
T5 1808-1819 Phenotype denotes Retinopathy http://purl.obolibrary.org/obo/HP_0000488
T6 1882-1896 Phenotype denotes liver diseases http://purl.obolibrary.org/obo/HP_0001392
T7 2116-2127 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T8 2131-2153 Phenotype denotes prolonged QTc interval http://purl.obolibrary.org/obo/HP_0005184
T9 2182-2192 Phenotype denotes Myasthenia http://purl.obolibrary.org/obo/HP_0003473
T10 2287-2300 Phenotype denotes Hypoglycaemia http://purl.obolibrary.org/obo/HP_0001943
T11 2618-2637 Phenotype denotes atrial fibrillation http://purl.obolibrary.org/obo/HP_0005110
T12 4330-4367 Phenotype denotes Chronic Obstructive Pulmonary Disease http://purl.obolibrary.org/obo/HP_0006510
T13 4679-4700 Phenotype denotes chronic lung diseases http://purl.obolibrary.org/obo/HP_0006528
T14 4702-4706 Phenotype denotes COPD http://purl.obolibrary.org/obo/HP_0006510
T15 4708-4714 Phenotype denotes asthma http://purl.obolibrary.org/obo/HP_0002099
T16 4716-4730 Phenotype denotes bronchiectasis http://purl.obolibrary.org/obo/HP_0002110
T17 4732-4757 Phenotype denotes interstitial lung disease http://purl.obolibrary.org/obo/HP_0006530

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 361-373 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T2 1458-1466 http://purl.obolibrary.org/obo/GO_0042696 denotes menarche
T3 1496-1508 http://purl.obolibrary.org/obo/GO_0042703 denotes menstruation
T4 1708-1724 http://purl.obolibrary.org/obo/GO_0002524 denotes hypersensitivity
T5 1781-1788 http://purl.obolibrary.org/obo/GO_0007605 denotes hearing
T6 2038-2042 http://purl.obolibrary.org/obo/GO_0005006 denotes eGFR
T7 2087-2105 http://purl.obolibrary.org/obo/GO_0061337 denotes cardiac conduction

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-117 Sentence denotes Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID):
T2 118-193 Sentence denotes A structured summary of a study protocol for a randomised controlled trial.
T3 194-205 Sentence denotes OBJECTIVES:
T4 206-686 Sentence denotes The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death.
T5 687-700 Sentence denotes TRIAL DESIGN:
T6 701-808 Sentence denotes This is a multi-centre, randomised, Placebo-controlled, 2-arm ratio 1:1, parallel group double-blind study.
T7 809-822 Sentence denotes PARTICIPANTS:
T8 823-927 Sentence denotes 226 participants are recruited at the trial sites/hospitals, where the study will take place in Denmark:
T9 928-1017 Sentence denotes Aalborg, Bispebjerg, Gentofte, Herlev, Hillerød, Hvidovre, Odense and Slagelse hospitals.
T10 1018-1301 Sentence denotes INCLUSION CRITERIA: • Patient admitted to Danish emergency departments, respiratory medicine departments or internal medicine departments • Age≥ 18 years • Hospitalized ≤48 hours • Positive COVID-19 test / diagnosis during the hospitalization (confirmed). • Men or non-fertile women.
T11 1302-2613 Sentence denotes Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion • Informed consent signed by the patient *Defined as after menarche and until postmenopausal (no menstruation for 12 months) Exclusion criteria: • At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured) • Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives • Neurogenic hearing loss • Psoriasis • Retinopathy • Maculopathy • Visual field changes • Breastfeeding • Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously) • Severe gastrointestinal, neurological and hematological disorders (investigator-assessed) • eGFR <45 ml/min/1.73 m2 • Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms). • Myasthenia gravis • Treatment with digoxin* • Glucose-6-phosphate dehydrogenase deficiency • Porphyria • Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L) • Severe mental illness which significantly impedes cooperation • Severe linguistic problems that significantly hinder cooperation • Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention.
T12 2614-2717 Sentence denotes For atrial fibrillation/flutter, select according to the Cardiovascular National Treatment Guide (NBV):
T13 2718-2797 Sentence denotes Calcium antagonist, Beta blocker, direct current (DC) conversion or amiodarone.
T14 2798-2967 Sentence denotes In case of urgent need for digoxin treatment (contraindication for the aforementioned equal alternatives), the test drug should be paused, and ECG should be taken daily.
T15 2968-2996 Sentence denotes INTERVENTION AND COMPARATOR:
T16 2997-3011 Sentence denotes Control group:
T17 3012-3131 Sentence denotes The control group will receive the standard treatment + placebo for both types of intervention medication at all times.
T18 3132-3282 Sentence denotes If part or all the intervention therapy being investigated becomes standard treatment during the study, this may also be offered to the control group.
T19 3283-3302 Sentence denotes Intervention group:
T20 3303-3374 Sentence denotes The patients in the intervention group will also receive standard care.
T21 3375-3472 Sentence denotes Immediately after randomisation to the intervention group, the patient will begin treatment with:
T22 3473-3486 Sentence denotes Azithromycin:
T23 3487-3495 Sentence denotes Day 1-3:
T24 3496-3516 Sentence denotes 500 mg x 1 Day 4-15:
T25 3517-3872 Sentence denotes 250 mg x 1 If the patient is unable to take the medication orally by themselves, the medication will, if possible, be administered by either stomach-feeding tube, or alternatively, temporary be changed to clarithromycin 500 mg x 2 (this only in agreement with either study coordinator Pradeesh Sivapalan or principal investigator Jens-Ulrik Stæhr Jensen).
T26 3873-3930 Sentence denotes This will also be done in the control group if necessary.
T27 3931-3990 Sentence denotes The patient will switch back to azithromycin when possible.
T28 3991-4010 Sentence denotes Hydroxychloroquine:
T29 4011-4087 Sentence denotes Furthermore, the patient will be treated with hydroxychloroquine as follows:
T30 4088-4097 Sentence denotes Day 1-15:
T31 4098-4316 Sentence denotes 200 mg x 2 MAIN OUTCOMES: • Number of days alive and discharged from hospital within 14 days (summarises both whether the patient is alive and discharged from hospital) ("Days alive and out of hospital") RANDOMISATION:
T32 4317-4428 Sentence denotes The sponsor (Chronic Obstructive Pulmonary Disease Trial Network, COP:TRIN) generates a randomisation sequence.
T33 4429-4544 Sentence denotes Randomisation will be in blocks of unknown size and the final allocation will be via an encrypted website (REDCap).
T34 4545-4771 Sentence denotes There will be stratification for age (>70 years vs. <=70 years), site of recruitment and whether the patient has any of the following chronic lung diseases: COPD, asthma, bronchiectasis, interstitial lung disease (Yes vs. No).
T35 4772-4791 Sentence denotes BLINDING (MASKING):
T36 4792-4914 Sentence denotes Participants and study personnel will both be blinded, i.e. neither will know which group the participant is allocated to.
T37 4915-4954 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T38 4955-5026 Sentence denotes This study requires 226 patients randomised 1:1 with 113 in each group.
T39 5027-5040 Sentence denotes TRIAL STATUS:
T40 5041-5083 Sentence denotes Protocol version 1.8, from April 16, 2020.
T41 5084-5204 Sentence denotes Recruitment is ongoing (first patient recruited April 6, 2020; final patient expected to be recruited October 31, 2020).
T42 5205-5224 Sentence denotes TRIAL REGISTRATION:
T43 5225-5310 Sentence denotes ClinicalTrials.gov Identifier: NCT04322396 (registered March 26, 2020) FULL PROTOCOL:
T44 5311-5419 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T45 5420-5600 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
T46 5601-5685 Sentence denotes The study protocol has been reported in accordance with the Standard Protocol Items:
T47 5686-5777 Sentence denotes Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 1659-1666 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T2 1708-1724 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T3 1781-1793 Phenotype denotes hearing loss http://purl.obolibrary.org/obo/HP_0000365
T4 1796-1805 Phenotype denotes Psoriasis http://purl.obolibrary.org/obo/HP_0003765
T5 1808-1819 Phenotype denotes Retinopathy http://purl.obolibrary.org/obo/HP_0000488
T6 1882-1896 Phenotype denotes liver diseases http://purl.obolibrary.org/obo/HP_0001392
T7 2116-2127 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T8 2131-2153 Phenotype denotes prolonged QTc interval http://purl.obolibrary.org/obo/HP_0005184
T9 2182-2192 Phenotype denotes Myasthenia http://purl.obolibrary.org/obo/HP_0003473
T10 2287-2300 Phenotype denotes Hypoglycaemia http://purl.obolibrary.org/obo/HP_0001943
T11 2618-2637 Phenotype denotes atrial fibrillation http://purl.obolibrary.org/obo/HP_0005110
T12 4330-4367 Phenotype denotes Chronic Obstructive Pulmonary Disease http://purl.obolibrary.org/obo/HP_0006510
T13 4679-4700 Phenotype denotes chronic lung diseases http://purl.obolibrary.org/obo/HP_0006528
T14 4702-4706 Phenotype denotes COPD http://purl.obolibrary.org/obo/HP_0006510
T15 4708-4714 Phenotype denotes asthma http://purl.obolibrary.org/obo/HP_0002099
T16 4716-4730 Phenotype denotes bronchiectasis http://purl.obolibrary.org/obo/HP_0002110
T17 4732-4757 Phenotype denotes interstitial lung disease http://purl.obolibrary.org/obo/HP_0006530

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-117 Sentence denotes Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID):
T2 118-193 Sentence denotes A structured summary of a study protocol for a randomised controlled trial.
T3 194-205 Sentence denotes OBJECTIVES:
T4 206-686 Sentence denotes The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death.
T5 687-700 Sentence denotes TRIAL DESIGN:
T6 701-808 Sentence denotes This is a multi-centre, randomised, Placebo-controlled, 2-arm ratio 1:1, parallel group double-blind study.
T7 809-822 Sentence denotes PARTICIPANTS:
T8 823-927 Sentence denotes 226 participants are recruited at the trial sites/hospitals, where the study will take place in Denmark:
T9 928-1017 Sentence denotes Aalborg, Bispebjerg, Gentofte, Herlev, Hillerød, Hvidovre, Odense and Slagelse hospitals.
T10 1018-1301 Sentence denotes INCLUSION CRITERIA: • Patient admitted to Danish emergency departments, respiratory medicine departments or internal medicine departments • Age≥ 18 years • Hospitalized ≤48 hours • Positive COVID-19 test / diagnosis during the hospitalization (confirmed). • Men or non-fertile women.
T11 1302-2613 Sentence denotes Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion • Informed consent signed by the patient *Defined as after menarche and until postmenopausal (no menstruation for 12 months) Exclusion criteria: • At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured) • Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives • Neurogenic hearing loss • Psoriasis • Retinopathy • Maculopathy • Visual field changes • Breastfeeding • Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously) • Severe gastrointestinal, neurological and hematological disorders (investigator-assessed) • eGFR <45 ml/min/1.73 m2 • Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms). • Myasthenia gravis • Treatment with digoxin* • Glucose-6-phosphate dehydrogenase deficiency • Porphyria • Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L) • Severe mental illness which significantly impedes cooperation • Severe linguistic problems that significantly hinder cooperation • Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention.
T12 2614-2717 Sentence denotes For atrial fibrillation/flutter, select according to the Cardiovascular National Treatment Guide (NBV):
T13 2718-2797 Sentence denotes Calcium antagonist, Beta blocker, direct current (DC) conversion or amiodarone.
T14 2798-2967 Sentence denotes In case of urgent need for digoxin treatment (contraindication for the aforementioned equal alternatives), the test drug should be paused, and ECG should be taken daily.
T15 2968-2996 Sentence denotes INTERVENTION AND COMPARATOR:
T16 2997-3011 Sentence denotes Control group:
T17 3012-3131 Sentence denotes The control group will receive the standard treatment + placebo for both types of intervention medication at all times.
T18 3132-3282 Sentence denotes If part or all the intervention therapy being investigated becomes standard treatment during the study, this may also be offered to the control group.
T19 3283-3302 Sentence denotes Intervention group:
T20 3303-3374 Sentence denotes The patients in the intervention group will also receive standard care.
T21 3375-3472 Sentence denotes Immediately after randomisation to the intervention group, the patient will begin treatment with:
T22 3473-3486 Sentence denotes Azithromycin:
T23 3487-3495 Sentence denotes Day 1-3:
T24 3496-3516 Sentence denotes 500 mg x 1 Day 4-15:
T25 3517-3872 Sentence denotes 250 mg x 1 If the patient is unable to take the medication orally by themselves, the medication will, if possible, be administered by either stomach-feeding tube, or alternatively, temporary be changed to clarithromycin 500 mg x 2 (this only in agreement with either study coordinator Pradeesh Sivapalan or principal investigator Jens-Ulrik Stæhr Jensen).
T26 3873-3930 Sentence denotes This will also be done in the control group if necessary.
T27 3931-3990 Sentence denotes The patient will switch back to azithromycin when possible.
T28 3991-4010 Sentence denotes Hydroxychloroquine:
T29 4011-4087 Sentence denotes Furthermore, the patient will be treated with hydroxychloroquine as follows:
T30 4088-4097 Sentence denotes Day 1-15:
T31 4098-4316 Sentence denotes 200 mg x 2 MAIN OUTCOMES: • Number of days alive and discharged from hospital within 14 days (summarises both whether the patient is alive and discharged from hospital) ("Days alive and out of hospital") RANDOMISATION:
T32 4317-4428 Sentence denotes The sponsor (Chronic Obstructive Pulmonary Disease Trial Network, COP:TRIN) generates a randomisation sequence.
T33 4429-4544 Sentence denotes Randomisation will be in blocks of unknown size and the final allocation will be via an encrypted website (REDCap).
T34 4545-4771 Sentence denotes There will be stratification for age (>70 years vs. <=70 years), site of recruitment and whether the patient has any of the following chronic lung diseases: COPD, asthma, bronchiectasis, interstitial lung disease (Yes vs. No).
T35 4772-4791 Sentence denotes BLINDING (MASKING):
T36 4792-4914 Sentence denotes Participants and study personnel will both be blinded, i.e. neither will know which group the participant is allocated to.
T37 4915-4954 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T38 4955-5026 Sentence denotes This study requires 226 patients randomised 1:1 with 113 in each group.
T39 5027-5040 Sentence denotes TRIAL STATUS:
T40 5041-5083 Sentence denotes Protocol version 1.8, from April 16, 2020.
T41 5084-5204 Sentence denotes Recruitment is ongoing (first patient recruited April 6, 2020; final patient expected to be recruited October 31, 2020).
T42 5205-5224 Sentence denotes TRIAL REGISTRATION:
T43 5225-5310 Sentence denotes ClinicalTrials.gov Identifier: NCT04322396 (registered March 26, 2020) FULL PROTOCOL:
T44 5311-5419 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T45 5420-5600 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
T46 5601-5685 Sentence denotes The study protocol has been reported in accordance with the Standard Protocol Items:
T47 5686-5777 Sentence denotes Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
T1 0-117 Sentence denotes Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID):
T2 118-193 Sentence denotes A structured summary of a study protocol for a randomised controlled trial.
T3 194-205 Sentence denotes OBJECTIVES:
T4 206-686 Sentence denotes The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation duration for patients with COVID-19 (measured as "days alive and out of hospital" as the primary outcome), reduce the risk of non- invasive ventilation, treatment in the intensive care unit and death.
T5 687-700 Sentence denotes TRIAL DESIGN:
T6 701-808 Sentence denotes This is a multi-centre, randomised, Placebo-controlled, 2-arm ratio 1:1, parallel group double-blind study.
T7 809-822 Sentence denotes PARTICIPANTS:
T8 823-927 Sentence denotes 226 participants are recruited at the trial sites/hospitals, where the study will take place in Denmark:
T9 928-1017 Sentence denotes Aalborg, Bispebjerg, Gentofte, Herlev, Hillerød, Hvidovre, Odense and Slagelse hospitals.
T10 1018-1301 Sentence denotes INCLUSION CRITERIA: • Patient admitted to Danish emergency departments, respiratory medicine departments or internal medicine departments • Age≥ 18 years • Hospitalized ≤48 hours • Positive COVID-19 test / diagnosis during the hospitalization (confirmed). • Men or non-fertile women.
T11 1302-2613 Sentence denotes Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion • Informed consent signed by the patient *Defined as after menarche and until postmenopausal (no menstruation for 12 months) Exclusion criteria: • At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured) • Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives • Neurogenic hearing loss • Psoriasis • Retinopathy • Maculopathy • Visual field changes • Breastfeeding • Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously) • Severe gastrointestinal, neurological and hematological disorders (investigator-assessed) • eGFR <45 ml/min/1.73 m2 • Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms). • Myasthenia gravis • Treatment with digoxin* • Glucose-6-phosphate dehydrogenase deficiency • Porphyria • Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L) • Severe mental illness which significantly impedes cooperation • Severe linguistic problems that significantly hinder cooperation • Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention.
T12 2614-2717 Sentence denotes For atrial fibrillation/flutter, select according to the Cardiovascular National Treatment Guide (NBV):
T13 2718-2797 Sentence denotes Calcium antagonist, Beta blocker, direct current (DC) conversion or amiodarone.
T14 2798-2967 Sentence denotes In case of urgent need for digoxin treatment (contraindication for the aforementioned equal alternatives), the test drug should be paused, and ECG should be taken daily.
T15 2968-2996 Sentence denotes INTERVENTION AND COMPARATOR:
T16 2997-3011 Sentence denotes Control group:
T17 3012-3131 Sentence denotes The control group will receive the standard treatment + placebo for both types of intervention medication at all times.
T18 3132-3282 Sentence denotes If part or all the intervention therapy being investigated becomes standard treatment during the study, this may also be offered to the control group.
T19 3283-3302 Sentence denotes Intervention group:
T20 3303-3374 Sentence denotes The patients in the intervention group will also receive standard care.
T21 3375-3472 Sentence denotes Immediately after randomisation to the intervention group, the patient will begin treatment with:
T22 3473-3486 Sentence denotes Azithromycin:
T23 3487-3495 Sentence denotes Day 1-3:
T24 3496-3516 Sentence denotes 500 mg x 1 Day 4-15:
T25 3517-3872 Sentence denotes 250 mg x 1 If the patient is unable to take the medication orally by themselves, the medication will, if possible, be administered by either stomach-feeding tube, or alternatively, temporary be changed to clarithromycin 500 mg x 2 (this only in agreement with either study coordinator Pradeesh Sivapalan or principal investigator Jens-Ulrik Stæhr Jensen).
T26 3873-3930 Sentence denotes This will also be done in the control group if necessary.
T27 3931-3990 Sentence denotes The patient will switch back to azithromycin when possible.
T28 3991-4010 Sentence denotes Hydroxychloroquine:
T29 4011-4087 Sentence denotes Furthermore, the patient will be treated with hydroxychloroquine as follows:
T30 4088-4097 Sentence denotes Day 1-15:
T31 4098-4316 Sentence denotes 200 mg x 2 MAIN OUTCOMES: • Number of days alive and discharged from hospital within 14 days (summarises both whether the patient is alive and discharged from hospital) ("Days alive and out of hospital") RANDOMISATION:
T32 4317-4428 Sentence denotes The sponsor (Chronic Obstructive Pulmonary Disease Trial Network, COP:TRIN) generates a randomisation sequence.
T33 4429-4544 Sentence denotes Randomisation will be in blocks of unknown size and the final allocation will be via an encrypted website (REDCap).
T34 4545-4771 Sentence denotes There will be stratification for age (>70 years vs. <=70 years), site of recruitment and whether the patient has any of the following chronic lung diseases: COPD, asthma, bronchiectasis, interstitial lung disease (Yes vs. No).
T35 4772-4791 Sentence denotes BLINDING (MASKING):
T36 4792-4914 Sentence denotes Participants and study personnel will both be blinded, i.e. neither will know which group the participant is allocated to.
T37 4915-4954 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T38 4955-5026 Sentence denotes This study requires 226 patients randomised 1:1 with 113 in each group.
T39 5027-5040 Sentence denotes TRIAL STATUS:
T40 5041-5083 Sentence denotes Protocol version 1.8, from April 16, 2020.
T41 5084-5204 Sentence denotes Recruitment is ongoing (first patient recruited April 6, 2020; final patient expected to be recruited October 31, 2020).
T42 5205-5224 Sentence denotes TRIAL REGISTRATION:
T43 5225-5310 Sentence denotes ClinicalTrials.gov Identifier: NCT04322396 (registered March 26, 2020) FULL PROTOCOL:
T44 5311-5419 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T45 5420-5600 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
T46 5601-5685 Sentence denotes The study protocol has been reported in accordance with the Standard Protocol Items:
T47 5686-5777 Sentence denotes Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).